Alector, Inc. (ALEC)
$
1.96
+0.14 (7.14%)
Key metrics
Financial statements
Free cash flow per share
-1.9258
Market cap
213.9 Million
Price to sales ratio
3.0984
Debt to equity
0.6563
Current ratio
3.7565
Income quality
1.8320
Average inventory
0
ROE
-1.2302
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Alector, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for neurodegenerative diseases. The company’s EBITDA is -$136,156,000.00 a key indicator of its operational profitability. Alongside this, Alector reported depreciation and amortization expenses of $8,841,000.00 reflecting the wear and tear of its assets. Its gross profit ratio stands at 1.00 illustrating the efficiency of the company’s production and sales operations. Furthermore, the diluted EPS is -$1.23 accounting for potential share dilution. The company's stock is identified with the symbol 'ALEC' in the market, making it accessible for investors interested in its innovative offerings. Alector’s product pipeline includes AL001, a humanized recombinant monoclonal antibody, currently in Phase III clinical trials for treating frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis. Additionally, AL101 is undergoing Phase I clinical trials for neurodegenerative diseases, such as Alzheimer's and Parkinson's. The company also has AL002, a product candidate in Phase II trials for Alzheimer's disease, and AL003, which is in Phase I trials. Moreover, AL044, aimed at MS4A4A, a risk gene for Alzheimer's, is in the development stage. Alector maintains a collaboration agreement with Adimab, LLC for antibody research and development, as well as a strategic collaboration with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies like AL001 and AL101. The stock is affordable at $3.03 making it suitable for budget-conscious investors. It also boasts a high average trading volume of 1,333,390.00 indicating strong liquidity. With a market capitalization of $213,935,960.00 Alector is classified as a small-cap player in the biopharmaceutical sector. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field.
Is Alector, Inc. (ALEC) a good investment?
Investing in Alector, Inc. (ALEC) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as D+, with a Bearish outlook. Always conduct your own research before investing.
What is Alector, Inc. (ALEC)'s stock forecast?
Analysts predict Alector, Inc. stock to fluctuate between $0.87 (low) and $3.40 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Alector, Inc.'s market capitalization?
As of 2026-02-06, Alector, Inc.'s market cap is $213,935,960, based on 109,151,000 outstanding shares.
How does Alector, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Alector, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Alector, Inc. (ALEC) stock?
To buy Alector, Inc. (ALEC) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ALEC. Place an order (Market, Limit, etc.).
What is the best time to invest in Alector, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Alector, Inc. perform in the last earnings report?
Revenue: $100,558,000 | EPS: -$1.23 | Growth: -21.15%.
Where can I find Alector, Inc.'s investor relations reports?
Visit https://www.alector.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Alector, Inc.?
You can explore historical data from here
What is the all-time high and low for Alector, Inc. stock?
All-time high: $29.30 (2021-09-02) | All-time low: $0.87 (2025-04-09).
What are the key trends affecting Alector, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
globenewswire.com
SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced that Neil Berkley, who has served as Alector's Chief Business Officer (CBO) since March 2024, and CBO and Interim Chief Financial Officer (CFO) since June 2025, has been appointed CFO, effective December 10, 2025. Mr. Berkley will continue to serve as CBO.
seekingalpha.com
Alector, Inc. (ALEC) Presents at BofA Securities CNS Therapeutics Virtual Conference 2025 Transcript
globenewswire.com
LOS ANGELES, Nov. 26, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Alector, Inc. (“Alector” or “the Company”) (NASDAQ: ALEC) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
zacks.com
ALEC stock plunges after its dementia candidate fails to slow disease progression in a late-stage study, prompting job cuts and a strategic pipeline shift.
businesswire.com
LOS ANGELES--(BUSINESS WIRE)---- $ALEC--ALEC Investors Have Opportunity to Join Alector, Inc. Fraud Investigation with the Schall Law Firm.
zacks.com
Alector (ALEC) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.43 per share a year ago.
benzinga.com
On Tuesday, Alector, Inc. (NASDAQ:ALEC) announced results from the Phase 3 INFRONT-3 trial evaluating latozinemab (AL001) for frontotemporal dementia caused by a progranulin gene mutation (FTD- GRN ).
globenewswire.com
Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint Treatment did not slow progression of FTD as measured by the clinical co-primary endpoint
reuters.com
Alector said on Tuesday its experimental drug failed to slow the progression of a rare form of dementia in a late-stage trial, prompting the company to end the study and cut nearly half its workforce.
seekingalpha.com
Alector, Inc. - Special Call Company Participants Katie Hogan - Senior Director of Corporate Communication & Investor Relations Sara Kenkare-Mitra - President and Head of Research & Development Arnon Rosenthal - Co-Founder, CEO & Director Giacomo Salvadore - Chief Medical Officer Conference Call Participants Pete Stavropoulos - Cantor Fitzgerald & Co., Research Division Myles Minter - William Blair & Company L.L.C., Research Division Thomas Shrader - BTIG, LLC, Research Division Steven Alexopoulos - TD Cowen, Research Division Julian Pino - Stifel, Nicolaus & Company, Incorporated, Research Division Alec Stranahan - BofA Securities, Research Division Graig Suvannavejh - Mizuho Securities USA LLC, Research Division Presentation Operator Good morning, ladies and gentlemen, and welcome to Alector's conference call and webcast highlighting its progranulin franchise and Alector Brain Carrier programs.
See all news
